Back to Search
Start Over
Breast Cancer and Tamoxifen: A Nigerian Perspective to Effective Personalised Therapy
- Source :
- Breast Cancer : Targets and Therapy
- Publication Year :
- 2020
- Publisher :
- Dove, 2020.
-
Abstract
- Estrogen-receptor positivity in tumour, often requiring long-term tamoxifen therapy, is thought to characterise between 43% and 65% of breast cancer cases in Nigeria. The patient population is further marked by late-stage diagnosis which significantly heightens the tendency for tumour relapse in the course of tamoxifen therapy. Despite tamoxifen being considered a reliable chemopreventive in high-risk individuals and an effective adjuvant therapy for hormone-sensitive tumours, mortality has remained high among breast cancer patients in the West African region where Nigeria belongs. The Nigerian breast cancer population, like other similar patient-populations in the West African region, provides a mix of intrinsic genome-diversity and perhaps unique tumour biology and evolution. These peculiarities suggest the need for a rational approach to tumour management and a personalised delivery of therapy in Nigeria’s dominant estrogen-receptor-positive patient population. Herein, critical indices of tamoxifen-therapy success are discussed in the context of the Nigerian breast cancer population with emphasis on salient aspects of tamoxifen-biotransformation, host- and tumour-genomics, and epigenetics.
Details
- Language :
- English
- ISSN :
- 11791314
- Volume :
- 12
- Database :
- OpenAIRE
- Journal :
- Breast Cancer : Targets and Therapy
- Accession number :
- edsair.pmid..........6f2833119f4d171219052314a29964af